Although these conditions are rare, a proportion of patients with interstitial lung diseases
(ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It
represents a collaborative effort among the American Thoracic Society, Japanese …

Background The purpose of this analysis is to provide evidence-based and consensus-
derived guidance for clinicians to improve individual diagnostic decision-making for …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Hypersensitivity pneumonitis (HP) is a complex syndrome caused by the inhalation of a
variety of antigens in susceptible and sensitized individuals. These antigens are found in the …

Hypersensitivity pneumonitis (HP) is a complex syndrome resulting from repeated exposure
to a variety of organic particles. HP may present as acute, subacute, or chronic clinical forms …

Hypersensitivity pneumonitis (HP) is a complex and heterogeneous interstitial lung disease
(ILD) that occurs when susceptible individuals develop an exaggerated immune response to …

Hypersensitivity pneumonia (HP) is an interstitial lung disease (ILD) caused by sensitization
to an inhaled antigen. Although the reported inciting antigens are numerous, most are …

Background The treatment of chronic hypersensitivity pneumonitis (cHP) often includes
systemic oral corticosteroids, but the optimal pharmacologic management remains unclear …